85%Confidence
0Views
FDASource
2026-05-26Date
Summary
JB Chemicals' enalapril tablets failed impurity specifications, indicating poor manufacturing controls that may lead to regulatory action and product shortages. This could disrupt supply for Rising Pharma and create opportunities for competitors.
Actionable: Reduce exposure to JB Chemicals and Rising Pharma, and consider alternative enalapril suppliers.
AI Confidence: 85%
Data Points
firmJB Chemicals and Pharmaceuticals Ltd
classificationClass II
statusOngoing
distributionNationwide in the USA
productEnalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Ph
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now